MXCT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
7.3M
-24.7%
9.7M
+32.2%
7.3M
+6.9%
6.8M
-19.7%
8.5M
Cost of Revenue
1.7M
+6.8%
1.6M
-2.5%
1.6M
+0.9%
1.6M
+5.1%
1.5M
Gross Profit
5.6M
-30.8%
8.1M
+42.0%
5.7M
+8.7%
5.2M
-25.1%
7.0M
Operating Expenses
15.8M
+10.9%
14.3M
-15.7%
16.9M
-12.7%
19.4M
-8.6%
21.2M
R&D
4.3M
+10.3%
3.9M
+15.7%
3.3M
-37.3%
5.3M
-15.2%
6.3M
SG&A
10.6M
+13.1%
9.4M
+4.5%
9.0M
-9.8%
10.0M
-28.1%
13.9M
Operating Income
-10232000
-65.4%
-6185000
+44.9%
-11226000
+20.7%
-14149000
+0.5%
-14227000
EBITDA
-9254000
-80.1%
-5138000
-45.1%
-3542000
+72.9%
-13077000
+0.4%
-13127000
Net Income
-8874000
-86.8%
-4750000
+50.5%
-9596000
+22.7%
-12416000
-0.5%
-12357000
EPS (Basic)
$-0.08
-100.0%
$-0.04
+55.6%
$-0.09
+25.0%
$-0.12
+0.0%
$-0.12
EPS (Diluted)
$-0.08
-100.0%
$-0.04
+55.6%
$-0.09
+25.0%
$-0.12
+0.0%
$-0.12
Shares (Diluted)
106.8M
-0.0%
106.9M
+0.1%
106.7M
+0.1%
106.6M
+0.2%
106.4M
MaxCyte (MXCT) โ€” Financials